Adenovirus Infections in Hematologic Malignancy and Hematopoietic Cell Transplant Recipients: Epidemiology, Diagnosis, and Management Authors: Scott Schoninger, Hyeon Mu Jang, Yeon Joo Lee Published: 2026 ABSTRACT AbstractHuman adenovirus (HAdV) infection represents a significant cause of morbidity and mortality in patients with hematologic malignancies, particularly following allogeneic hematopoietic stem cell transplant. Clinical manifestations range from asymptomatic DNAemia to pneumonitis, enterocolitis, hepatitis, hemorrhagic cystitis, myocarditis, and central nervous system disease. Advances in molecular diagnostics, including quantitative polymerase chain reaction, have enabled earlier detection and surveillance, yet interpretation remains challenging given the absence of standardized viral load thresholds and international quantitative standards. Reported incidence varies by age, transplant type, geographic regions, and surveillance strategy, with pediatric recipients demonstrating higher infection rates, while mortality among patients with DNAemia or disseminated disease remains substantial. Risk factors include T-cell depletion, cord blood transplant, severe graft-versus-host disease, high-dose corticosteroid exposure, and delayed immune reconstitution. Management relies primarily on immune recovery and reduction of immunosuppression when feasible. Intravenous cidofovir remains the most widely used antiviral despite nephrotoxicity, while intravenous brincidofovir represents a potentially promising emerging approach. The impact of contemporary transplant approaches, including post-transplant cyclophosphamide and novel cellular therapies, on HAdV epidemiology requires further study. This review summarizes contemporary epidemiology, definitions, diagnostic strategies, and evolving therapeutic options for HAdV infection in patients with hematologic malignancies, highlighting ongoing challenges.Keywords: Adenovirus, Immunocompromised, Hematopoietic stem cell transplant, Hematologic malignancies Introduction Human adenoviruses (HAdV) represent a group of 7 species of the viral family Adenoviridae, genus Mastadenovirus, known to cause a wide spectrum of clinical disease in humans [1]. HAdVs are large, non-enveloped, icosahedral, double-stranded DNA viruses, which have been classified into 51 serotypes, and now 116 genotypes [1]. HAdVs have several virulence factors, including thermostability, as well as the ability to establish latent infection in mucosal lymphocytes, leading to the potential for future reactivation in the setting of severe immunocompromise, including allogeneic hematopoietic stem cell transplant (HCT) recipients [2,3]. The most common clinical presentations in the community are upper respiratory infections, gastroenteritis, and conjunctivitis. While many serotypes can cause upper respiratory tract infections and pneumonia, a more limited set of serotypes are known to cause ocular infection, and gastroenteritis, mostly confined to outbreaks, is generally only associated with genotypes 40 and 41 of species F. Several serotypes have been associated with severe presentations, both in the immunocompetent and immunocompromised settings. In immunocompetent patients, severe respiratory infections including pneumonia have most frequently been identified in epidemics associated with species B (serotypes 3, 7, 11, 14, and 21), as well as HAdV-4 of species E, which has been historically associated with outbreaks among military recruits, but more recently discovered in community outbreaks as well [4,5,6]. Similarly, among 4 non-transplant cancer patients with severe lower respiratory presentations, species B and E were identified [7]. In immunocompromised patients, defects in cell-mediated immunity and the potential for reactivation of latent infection increases the diversity of presentations and of the causative pathogenic strains. Wide ranges of incidences and mortality have been reported across studies, with a recent meta-analysis supporting an overall incidence of infection (including asymptomatic patients) at about 7%, with mortality around 17% among adult allogeneic HCT recipients [8]. Graft and recipient factors which affect T-cell function, such as T-cell depletion and receipt of additional immunosuppressants to treat graft-versus-host disease (GVHD), which decrease the effectiveness of cell-mediated immunity, have also been shown in some studies to increase the risk of severe HAdV infection [9,10]. The purpose of this review is to summarize the clinical manifestations, diagnosis, epidemiology, risk factors, and management strategies in patients with hematologic malignancies, with a particular focus on allogeneic HCT recipients. Clinical manifestations and definitions of adenovirus infections HAdV is frequently detected in asymptomatic HCT patients due to the sensitivity of molecular techniques such as polymerase chain reaction (PCR), yielding the distinction between HAdV infection and disease. Research into the incidence, morbidity, and mortality associated with HAdV infection has been complicated by the lack of standardized definitions, which is likely a partial explanation as to the wide ranges reported for these values in studies. The first major published definitions related to HAdV in HCT recipients were published by the European Conference on Infections in Leukemia [11]. They defined systemic infection as the presence of HAdV DNAemia, whereas local infection was defined as HAdV detected in tissue or body fluids. Probable and proven disease were both defined by infection in the presence of compatible symptoms, with histologic confirmation required for proven disease. For pediatric patients, definitions were refined in 2024 and criteria were created for specific clinical diseases including febrile syndrome, upper respiratory infection, pneumonitis, colitis/enteritis, hepatitis, cystitis, carditis, and central nervous system (CNS) disease, with criteria for proven, probable, and possible disease, to be used in future clinical trials [12]. In this review, we use “infection” to refer to detection of HAdV in any compartment, “DNAemia” to refer to detection in blood, and “disease” to indicate organ involvement with compatible symptoms. HAdV can infect many organ systems, with severity ranging from asymptomatic carriage to fulminant disseminated disease. In immunocompetent hosts, presentations most commonly include upper respiratory infection, pharyngitis, conjunctivitis, and gastroenteritis. In children with asthma, it can trigger reactive airway disease and wheezing [13]. Transplant recipients can have these presentations, along with hepatitis, colitis, cystitis, myocarditis, and meningoencephalitis [9,14]. Both upper and lower respiratory tract infections are common presentations of HAdV in the HCT population. Isolated upper respiratory infection is defined as upper respiratory infection-type symptoms such as rhinorrhea, pharyngitis, or conjunctivitis, without lower respiratory tract signs or symptoms. Pneumonitis, in contrast, requires radiographic infiltrates and symptoms of respiratory distress. A positive upper respiratory tract sample can be used as a surrogate marker in possible disease, but probable disease requires a lower respiratory tract sample. It is important to note that HAdV detected in upper respiratory specimens may reflect prolonged DNA shedding from latent infection in tonsillar or adenoidal lymphoid tissue [2]. In adenoviral pneumonia, the most common imaging findings are focal consolidation, pleural effusions, septal thickening, and nodules, which can progress to bilateral consolidations as the disease progresses [15,16]. Non-productive cough, fever, and upper respiratory symptoms are frequently present [17]. In gastrointestinal (GI) infection, both the small and large intestine can be involved, defined as enteritis and colitis, respectively. Diagnosis hinges on endoscopic tissue biopsy. Presentations typically include diarrhea, which is bloody in roughly half of cases, along with abdominal pain, and less commonly bowel obstruction or associated symptoms such as nausea or vomiting [18]. Diagnosis can be complicated by the presence of comorbid GI GVHD or other infections such as cytomegalovirus. Hepatitis is a presentation which is rarely seen in the healthy population, though it can present post-allogeneic HCT, and is associated with high mortality [19]. Definitive diagnosis requires liver biopsy for both molecular testing and histopathologic examination, though a probable diagnosis can be made in situations of acute hepatitis with transaminitis in the setting of significantly increasing HAdV DNAemia without an alternative explanation. Hyperbilirubinemia is frequently seen but is not required for diagnosis [20]. Multiple hypodense lesions are frequently identified on computed tomography, which can be related to focal necrosis on histopathology, and may help with the differential diagnosis [19]. CNS disease is perhaps the most dreaded consequence of HAdV. Definitive diagnosis requires a tissue biopsy, though more commonly a probable diagnosis is established based on cerebrospinal fluid findings. Clinical findings can include meningitis, encephalitis, or both, with or without radiographic changes [21]. A series of two children who developed HAdV meningoencephalitis post allogeneic HCT both had periventricular hyperintensities on Magnetic Resonance Imaging, however no characteristic changes were identified on a larger retrospective series which was not limited to allogeneic HCT [22]. Interestingly, in the two children’s series, HAdV was not detectable in the blood of either child, suggesting that lack of HAdV DNAemia cannot be used to rule out HAdV as a cause of CNS infection [22]. HAdV carditis is another rare manifestation which can present with symptoms of myocarditis, or less commonly pericarditis. Diagnosis can be made by molecular detection of HAdV DNA in pericardial fluid when a pericardial effusion is present, but otherwise a myocardial biopsy is typically required for definitive diagnosis. Outbreaks of HAdV carditis have occurred in previously healthy children [23]. Complications can include arrhythmia and dilated cardiomyopathy [24]. HAdV can be detected in the urine, but its significance is harder to ascertain. Hemorrhagic cystitis is the most frequent presentation in symptomatic patients, but diagnosis is challenging due to the frequent presence of comorbid BK polyomavirus viruria, or cyclophosphamide toxicity [25]. Diagnostic approaches Diagnostic tests of HAdV infection in patients with hematologic malignancies and allogeneic HCT recipients rely primarily on molecular assays, with histopathology for confirmation of end-organ disease [1,11,26]. The choice of diagnostic modality depends on the clinical syndrome and transplant setting (Table 1). In clinical practice, plasma quantitative PCR and stool GI panel and PCR represent the most relevant and actionable diagnostic tools in HCT recipients and will therefore be emphasized in this review. Table 1Diagnostic modalities for adenovirus in hematologic malignancy and hematopoietic cell transplant recipientsSpecimenModalityDetects all genotypesQuantitativeStrengthLimitationsBest clinical useStoolMultiplex GI PCR panel [27]F40/41 onlyNoRapid, syndromicMiss non-enteric species (A-E) [28]Community-acquired diarrhea evaluationStoolStool PCRYesVariableEarly detection in pediatric allogeneic HCT recipients [32]Clinical significance uncertain in adultsPre-transplant screening in pediatric allogeneic HCT recipientsNasopharyngeal swab [85]Multiplex respiratory PCR panelVariable (newer panels broader coverage) [29,30]NoRapid, syndromicMay detect asymptomatic sheddingEvaluation of respiratory symptomsBloodQuantitative plasma PCRYesYesGold standard for surveillance [1]No WHO international standard; inter-lab variabilitySurveillance and preemptive monitoringBloodSerologyN/AN/ARisk stratification in pediatric allogeneic HCT recipients [39]Not commercially availableRisk assessment in pediatric allogeneic HCT recipientsGI, gastrointestinal; PCR, polymerase chain reaction; HCT, hematopoietic stem cell transplant; WHO, World Health Organization; N/A, not applicable. Diagnostic modalities for adenovirus in hematologic malignancy and hematopoietic cell transplant recipients GI, gastrointestinal; PCR, polymerase chain reaction; HCT, hematopoietic stem cell transplant; WHO, World Health Organization; N/A, not applicable. 1. Molecular assay Molecular diagnostic assays are most commonly used, including syndrome-based multiplex panels and targeted PCR-based tests. Multiplex GI panels such as the FilmArray GI panel (bioMérieux, Marcy-l’Etoile, France) detect HAdV types F40/41, which are the most common serotypes associated with community-acquired gastroenteritis [27], but do not identify non-enteric HAdV species (A-E) that commonly affect the oncology population [28]. Thus, multiplex GI panels have limited sensitivity for HAdV in immunocompromised patients. Syndromic respiratory virus panels detect multiple respiratory pathogens including HAdV in nasopharyngeal specimens, but results may reflect asymptomatic shedding. The challenge is frequently to determine the clinical relevance of this data, particularly when other pathogens are also detected, or non-infectious etiologies such as GVHD are on the differential. Newer platforms can detect a wider range of genotypes [29]. Detection of all genotypes is particularly important in immunocompromised patients, in whom HAdV infection may be caused by a broad range of genotypes. HAdV genotype detections can be variable depending on respiratory virus panel types [30]. 1) Quantitative PCR in blood Nucleic acid amplification techniques, including PCR-based molecular diagnostics, have become the standard diagnostic methods to detect HAdV, due to their high sensitivity and specificity [1,11,26]. Plasma PCR enables serial viral load monitoring to guide preemptive therapy and assess treatment response [1]. However, interpretation of HAdV DNAemia is complicated by the absence of a World Health Organization International Quantitative Standard, leading to inter-laboratory variability. 2) Stool PCR Persistent HAdV DNA is detectable in approximately one-third of intestinal tissue samples from immunocompetent children and adults, representative of latent infection of mucosal lymphocytes [3,31]. Stool PCR plays an important role in pediatric allogeneic HCT recipients. HAdV can be detected in the stool before detection in blood and before symptom onset in this population [32]. These findings suggest a potential role for stool PCR surveillance and pre-emptive intervention in high-risk pediatric HCT recipients, though robust prospective evidence remains lacking [33]. In contrast, the role of stool PCR surveillance in adult HCT recipients is not established. 2. Histopathology Histopathology is the gold standard for diagnosis of HAdV end-organ disease. Biopsy may not be feasible in patients with hematologic malignancy, and in HCT recipients, due to thrombocytopenia and bleeding risk. Viral cytopathic changes consist of enlarged nuclei containing dense basophilic intranuclear inclusions (smudge cells), characteristic of HAdV infection [34]. However, cytopathic changes of HAdV may be easily missed by H&E stain, thus the routine use of HAdV immunohistochemistry is recommended to confirm HAdV [35]. 3. Other diagnostic modalities Traditional methods such as viral culture, serology, and antigen detection play a limited role in contemporary practice for the diagnosis of HAdV infection [36]. Viral culture is labor-intensive and slow compared to PCR, making it impractical for routine clinical use [36]. Emerging technologies including droplet digital PCR and metagenomic next-generation sequencing may enhance HAdV detection, however their clinical utility remains under investigation [37,38]. Increasing usage of next generation whole-genome sequencing is expected to further expand the recognition of additional HAdV genotypes [1]. Pre-transplant serologic testing for HAdV antibodies, which is currently only available for use in research, may offer an alternative approach for risk stratification in HAdV in pediatric HCT recipients [39]. Epidemiology The incidence of HAdV infection varies depending on patients’ age, transplant type, conditioning regimen, and HAdV surveillance testing practices. The distribution of circulating HAdV genotypes may vary by geographic region. While several studies from Europe report predominance of HAdV species C among pediatric allogeneic HCT recipients, data from pediatric allogeneic HCT recipients in South Korea showed species B was most common [32,40,41,42]. Overall, HAdV infection is more common in pediatric than adult allogeneic HCT recipients, with reported rates ranging from 11% to 40.9% [40,41,42,43,44,45,46]. In adult allogeneic HCT recipients who undergo surveillance testing, HAdV DNAemia is reported in 3%-10% [8,10,47,48,49,50]. A recent meta-analysis of 25 studies, including 61,832 adult patients, reported a pooled incidence of HAdV infection (including asymptomatic patients) in HCT patients at 7.3%, with mortality at 16.7% [8]. The pooled incidence of HAdV DNAemia was 7.2%, with high level DNAemia (>1,000 copies/ml) in 3.4%. Overall mortality due to HAdV infection was 16.7%, with mortality due to DNAemia at 11.5% and high-level DNAemia at 24.0%. The incidence of HAdV disease was investigated in a Japanese registry analysis of 48,380 patients who underwent allogeneic HCT [51]. In that study, the 1-year cumulative incidence of HAdV disease was 1.52% in children and 2.99% in adults, with mortality at 56%. However, the most common HAdV disease in that study was genitourinary infection, typically hemorrhagic cystitis, which differs from most other published studies and suggests a possibility for regional variations in endemic viruses, and that the results may not be globally generalizable. A retrospective European study looked at 1,110 children and 1,419 adult allogeneic HCT recipients who developed HAdV infection after transplant [52]. In children, 68.5% of infections occurred prior to day +60 post allogeneic HCT, whereas in adults, 62.2% occurred after day +60. 1 year mortality was 42.2% in adults and 30.8% in children. In both children and adults, DNAemia was the most common infection, followed by GI infection. Factors associated with severe disease in children included CMV-seropositivity of the donor and/or recipient and poor performance status. In adults, HAdV DNAemia, second transplants, and early HAdV infection were associated with increased mortality. In vivo and ex-vivo T-cell depletion also approached statistical significance but notably stem cell source was not predictive. These risk factors for severe disease therefore differ from those that have been identified as risks for HAdV infection to present in the first place, which include T-cell depletion, cord blood allografts, severe GVHD requiring high dose steroids, and known HAdV positivity pre-transplant [14]. Post-transplant cyclophosphamide (PTCy) is an effective strategy for GVHD prophylaxis. It is the standard of care for haploidentical HCT [53] and is increasingly used for matched and mismatched donor HCT [54,55]. PTCy attenuates alloreactive T cells from the donor and recipient and induces the rapid and preferred recovery and expansion of regulatory T-cells [56]. However, data regarding the incidence and outcomes of HAdV infection in patients receiving PTCy-based GVHD prophylaxis remain limited. Table 2 summarizes published studies evaluating HAdV infection among patients with PTCy for GVHD prophylaxis. Across these studies, HAdV DNAemia occurred in approximately 3%-6.8% of adult allogeneic HCT recipients receiving PTCy-based GVHD prophylaxis, with higher rates in haploidentical compared to matched or mismatched unrelated donor recipients [49,50,57,58]. Overall, HAdV-attributable mortality ranged from 13% to 33.3% among patients who developed DNAemia or disease, with HAdV diseases or death occurring among patients with DNAemia >1,000 copies/mL, suggesting that high-level DNAemia is a key prognostic threshold in the PTCy setting [49,50,58]. Compared to historical non-PTCy cohorts reporting overall HAdV infection rates of approximately 7% and mortality of approximately 17% among adult allogeneic HCT recipients [8], PTCy-based GVHD prophylaxis does not appear to substantially increase HAdV risk overall. Because PTCy is increasingly used across donor platforms and has been associated with improved survival, its impact on viral reactivation, including HAdV infection, remains an important area of investigation. Table 2Adenovirus incidence, disease, and mortality after allogeneic hematopoietic cell transplant recipients using post-transplant cyclophosphamideStudy, yearStudy designPopulation and GVHD prophylaxisSurveillance strategyDefinitionsIncidence of HAdV DNAemia, median days from HCT (D)Incidence of HAdV disease, DHAdV attributable mortalityKey notesKerbauy et al. 2021 [57]Retrospective, single center127 adults (haplo HCT with PTCy-based GVHD ppx 59 patients)HAdV Plasma PCR weekly till immunosuppressionHAdV DNAemia 6.8% among haplo PTCy recipientsMultiple double-stranded DNA virus infections are a risk factor for worse overall survival.Balletto et al. 2024 [50]Retrospective, single center444 adults (haplo HCT with PTCy-based GVHD ppx 336 patients)HAdV Plasma PCR ≥2 monthly until D+30, then ≥1 monthly weekly until D+100, then testing only in patients with GVHD after D+100Systemic HAdV infection/DNAemia: positive HAdV DNA in peripheral bloodHAdV DNAemia 5% by D+180, D+6513% (all cases occurred among patients with maximum HAdV DNAemia >1,000 copies/mL)Haplo PTCy was not associated with HAdV infection.Local HAdV infection: positive HAdV or antigen detection in biopsy material or in body fluids other than peripheral bloodGVHD and diagnosis of lymphoproliferative disease were associated with HAdV infection.Little et al. 2024 [58]Retrospective, single center354 adults with PTCy-based GVHD ppx (193 haplo vs. 161 MUD/MMUD)Symptom-driven HAdV plasma PCR monitoringHAdV infection defined per ECIL-4 [11]HAdV infection (7% in haplo vs. 2% in MUD/MMUD), D+87In haplo, 42.8% localized HAdV disease and 42.8% disseminated disease3/14 (21.4%) in haplo vs. 1/3 (33.3%) in MUD/MMUD among patients with HAdV infectionHAdV infection was significantly increased among haplo.Gianniki et al. 2025 [49]Retrospective, single center412 adults with HCT PTCy-based GVHD ppx (158 haplo vs. 259 MUD/MMUD)HAdV Plasma PCR weekly till D+100, then ≥q 2 weeks until D+180Clinically significant HAdV DNAemia ≥1,000 copies/mL or ≥1 value ≥10,000 copies/mL by D+180Clinically significant HAdV DNAemia 3% by D+1802% overall by D+180; among clinically significant HAdV DNAemia, 66.6% (8/12) developed disease.Overall mortality among patients with clinically significant HAdV DNAemia 25% by D+180All HAdV disease cases were symptomatic at clinically significant DNAemia.GVHD, graft versus host disease; HCT, hematopoietic stem cell transplant; D, days post-transplant; PTCy, post-transplant cyclophosphamide; haplo, haploidentical donor; ppx, prophylaxis; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; ECIL, European Conference on Infections in Leukemia. Adenovirus incidence, disease, and mortality after allogeneic hematopoietic cell transplant recipients using post-transplant cyclophosphamide GVHD, graft versus host disease; HCT, hematopoietic stem cell transplant; D, days post-transplant; PTCy, post-transplant cyclophosphamide; haplo, haploidentical donor; ppx, prophylaxis; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; ECIL, European Conference on Infections in Leukemia. Adenovirus infection following autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T-cell therapy Although there has been a case report of disseminated infection, the incidence of HAdV infection after autologous HCT is rare, even with a T-cell-depleted autologous graft, likely reflecting a less profound and shorter duration of immunosuppression [59,60,61]. Recent Japanese registry study data showed the rate of HAdV disease after autologous HCT was 0.18% in children and 0.49% in adults, respectively [51]. Data on the epidemiology and clinical significance of HAdV infections after CAR T-cell therapy are limited. Reported cases are rare and have occurred both before and after day +30 of CD19 CAR T-cell therapy [62,63]. Given the rarity of reported HAdV infection and the absence of systemic prospective data, routine HAdV PCR surveillance is not recommended in CAR T-cell recipients [63]. Management Based on available evidence and current clinical practice, we propose a practice management algorithm for HAdV infection in allogeneic HCT recipients that integrates viral load thresholds, clinical symptoms, and host risk factors to guide monitoring and therapeutic decisions (Fig. 1), consistent with expert approaches to the prevention and management of viral reactivation in high-risk allogeneic HCT recipients [14,64,65]. High-risk allogeneic HCT recipients, including those with T-cell depletion, cord blood transplant, severe GVHD, or post-transplant cyclophosphamide–based GVHD prophylaxis, may undergo surveillance for HAdV infection. Management is guided by plasma viral load and clinical manifestations. Asymptomatic patients with low-level DNAemia (<1,000 copies/mL) may be monitored with serial viral load testing. Patients with intermediate DNAemia (1,000–10,000 copies/mL) and symptoms or those with high DNAemia (>10,000 copies/mL) or end-organ disease should be considered for initiation of antiviral therapy and reduction of immunosuppression when feasible. Serial monitoring of HAdV DNAemia is recommended to assess treatment response. In patients with persistent or progressive infection, adjunctive strategies such as virus-specific T-cell therapy or investigational antiviral agents may be considered. aThe impact of PTCy on HAdV risk is limited and requires further study. HCT, hematopoietic stem cell transplant; GVHD, graft versus host disease; PTCy, post-transplant cyclophosphamide; HAdV, human adenovirus. 1. Anti-viral therapy Treatment options for HAdV infection are limited, and immune reconstitution remains the key to controlling HAdV infection. Whenever feasible, reduction or withdrawal of immunosuppressive therapy should be prioritized [11,14,65,66]. There are no prospective randomized clinical trials, and no U.S. Food and Drug Administration (FDA) approved antiviral agents to treat HAdV infection. Intravenous cidofovir is used off-label and intravenous brincidofovir is currently under clinical investigation (ClinicalTrials.gov, NCT04706923). Ribavirin and ganciclovir have in-vitro activity, but their clinical utility is controversial [67]. In patients with low level asymptomatic HAdV DNAemia and adequate immune reconstitution, close monitoring without antiviral therapy may be appropriate, as spontaneous viral clearance can occur with recovery of T-cell immunity [68]. 1) Intravenous cidofovir Cidofovir is a monophosphate nucleotide analog of cytosine. Cidofovir is phosphorylated intracellularly to a diphosphate, facilitating its incorporation into viral DNA, where it acts as a competitive inhibitor of DNA polymerase and thereby inhibits viral replication [69,70]. It was initially used for severe cytomegalovirus infections in patients with acquired immunodeficiency syndrome (AIDS), and it was approved by the U.S. FDA in 1996 for cytomegalovirus retinitis in AIDS patients. Cidofovir is effective against all HAdV subtypes [71], although cidofovir-resistant mutations can be generated in vivo [72]. Cidofovir needs to be phosphorylated intracellularly for pharmacologic activity; however, more than 90% of the drug is excreted unchanged in the urine, and its hydrophilic structure limits cellular uptake, resulting in relatively low intracellular antiviral concentrations [73]. Intravenous cidofovir (3-5 mg/kg weekly for 2–3 weeks; thereafter, every other week) is commonly used despite its moderate risk of nephrotoxicity [11,65,73]. Given this concern, close monitoring of renal function, along with concomitant hydration and probenecid administration, are recommended for renal protection [65,74,75]. Antiviral therapy is generally initiated in patients with high-level DNAemia (typically >1,000 copies/mL with rising trajectory) or organ involvement, though no universally validated threshold exists. Table 3 summarizes key clinical studies published since 2017 evaluating cidofovir-based therapy for HAdV infection in HCT recipients. Interestingly, Thomas et al. reported that patients who did not receive antiviral therapy experienced earlier resolution of HAdV disease compared to those who received therapy. This finding requires caution, as the HAdV disease definition is broad and includes milder manifestations such as rash, conjunctivitis, and upper respiratory tract infection. Although the authors report that the finding persisted after adjustment for disseminated diseases, residual confounding by disease severity and immune status (T-cell reconstitution, lymphocyte count, GVHD) cannot be excluded, rather than antiviral therapy alone, in controlling HAdV infection [76]. Overall, the available evidence is derived from retrospective observational studies, with substantial heterogeneity in patient populations, transplant types, and outcome definitions. Table 3Clinical studies evaluating cidofovir based therapy for adenovirus infection in hematopoietic cell transplant recipients since the year of 2017Study, yearSample sizeStudy designHCT typesAge, median (range), yearsHAdV disease definitionCidofovir dosingSafetyEfficacyOutcomesGrasa et al. 2023 [86]49 episodes corresponding to 43 patients; 32 patients (74.4%) had received allogenic HCT (The rest of 11 patients received SOT)RetrospectiveAllogenic (transplant types are not specified)PediatricsHAdV DNAemia >1,000 copies/mL with symptoms attributed to HAdV infection including fever, respiratory disease, hematuria, and/or involvement of the gastrointestinal tract.5 mg/kg weeklyNephrotoxicity (12.5%)Symptom improvement: 70.8%; Virologic suppression (<1,000 copies/mL): 66.7%3 patients died due to HAdVStern et al. 2021 [87]165 allogeneic HCT recipients with double stranded DNA virus infection; HAdV infection 75 patients (45.5%)RetrospectiveAllogenic; Haploidentical donor: n=29 (17.7%); T cell depleted: n=89 (56.3%)50 years (IQR, 39–60)HAdV infection defined per ECIL-4 [11]An average weekly dose of 3.5 mg/kg (large variability)Nephrotoxicity (25.3%)Virological response (≥1 log reduction in DNAemia among patients with double stranded DNA virus infection): 51 (40.0%); 72% of HAdV infection26.1% of patients died within 28 days after last dose of cidofovirThomas et al. 2021 [76]93 patients with HAdV disease; Cidofovir Tx: n=18; Oral brincidofovir Tx: n=12; cidofovir + Oral brincidofovirTx: n=6RetrospectiveAllogenic (non-cord): n=13; Allogenic cord: n=77; Autologous: n=3PediatricsHAdV disease included conjunctivitis, rash, upper respiratory infection, pneumonia, hepatitis, hemorrhagic cystitis, gastroenteritis, myocarditis, or meningoencephalitis; 75% of single end-organ disease cases were enteritis/colitis, and 10 were upper respiratory infection.Large variability (specific dosing not available)Nephrotoxicity (n=2)Resolution of disease (improvement in end-organ dysfunction): 87% of all subjects. Patients who did not receive antiviral therapy experienced earlier resolution of HAdV disease compared to patients who received therapyMortality of patients treated with cidofovir: not available (mortality of patients with HAdV disease: 51.0%)HCT, hematopoietic stem cell transplant; HAdV, human adenovirus; SOT, solid organ transplant; IQR, interquartile range; ECIL-4, Fourth European Conference on Infections in Leukemia; Tx, treatment. Clinical studies evaluating cidofovir based therapy for adenovirus infection in hematopoietic cell transplant recipients since the year of 2017 HCT, hematopoietic stem cell transplant; HAdV, human adenovirus; SOT, solid organ transplant; IQR, interquartile range; ECIL-4, Fourth European Conference on Infections in Leukemia; Tx, treatment. 2) Oral brincidofovir Brincidofovir is a lipid conjugate of cidofovir. Its intracellular cleavage delivers cidofovir directly to the site of replication, which makes brincidofovir highly potent. Clinical trials have shown that brincidofovir decreases viral load with similar effectiveness across all clinically significant HAdV subtypes [77]. Compared with intravenous cidofovir, brincidofovir has better oral bioavailability and no nephrotoxicity, as it does not accumulate in the renal tubules [77]. However, its development for HAdV was discontinued due to significant GI toxicity; its current approved indication is limited to human smallpox [77,78]. 3) Intravenous brincidofovir Unlike oral brincidofovir, intravenous brincidofovir did not show potential hepatic and GI toxicities [79]. Phase 1 and phase 2 studies suggest a favorable safety profile, with a low risk of GI adverse effects [79,80]. Preliminary results from the ATHENA Phase 2a study showed that intravenous brincidofovir therapy cleared HAdV DNAemia in a dose-dependent manner [81]. A phase 3 trial evaluating intravenous brincidofovir versus intravenous cidofovir for the treatment of HAdV infection in adult and pediatric allogeneic HCT recipients is currently underway (ClinicalTrials.gov, NCT07387367). 2. Adoptive immunotherapy Adoptive immunotherapy involves the transfer of HAdV-specific cytotoxic T lymphocytes (CTLs) to enhance the immune response against HAdV. CTLs can be derived from a donor, either the stem cell transplant donor or third-party healthy donors [82]. Phase 2 single arm studies have demonstrated the safety of HAdV CTLs and shown promising results [83]. More recently, Cairo et al. reported preliminary results from an ongoing multicenter pilot study (ClinicalTrials.gov, NCT03266627) evaluating haploidentical donor-derived HAdV-specific CTLs in children, adolescents, and young adults with refractory HAdV infection following allogeneic HCT, solid organ transplant, or primary immunodeficiency. Among 15 enrolled patients, all of whom were post-allogeneic HCT, the overall response rate was 100%, and the complete response rate was 88%. No infusion-related toxicities were observed. Eight of 15 patients received CTLs from the original HCT donor, while the remaining 7 received third-party haploidentical donor-derived CTLs, demonstrating feasibility across both donor sources [84]. HAdV-specific CTLs are generally considered in patients with refractory DNAemia or progressive HAdV-associated end-organ disease despite cidofovir therapy, particularly when immune reconstitution is severely impaired. Donor-derived CTLs require availability of the original HCT donor, which may limit use in matched unrelated donor setting; third-party virus-specific T-cells offer an off-the-shelf alternative but are not widely available outside specialized centers. In clinical practice, adoptive immunotherapy for HAdV remains largely limited to academic centers with established cell therapy infrastructure. The most recent randomized trial evaluating an off-the-shelf commercial multivirus-specific CTL product (posoleucel; targeting HAdV, cytomegalovirus, BK polyomavirus, Epstein-Barr virus, human herpes 6 virus, and JC virus) for viral prevention following allogeneic HCT was stopped early after an interim futility analysis, without new safety concerns (clinicaltrials.gov/NCT05305040). Further data are needed to understand the reasons for the lack of efficacy observed in this trial, including patient selection, study design, product or other factors. Conclusion and Future Directions HAdV infection remains a clinically significant complication in patients with hematologic malignancies, particularly following allogeneic HCT. Despite advances in molecular diagnostics enabling earlier detection, management remains challenging due to the absence of standardized viral load thresholds, limited antiviral options, and the central role of impaired T-cell immunity in disease progression. While intravenous cidofovir remains the most commonly used therapy, its nephrotoxicity and modest virologic response rates underscore the need for safer and more effective treatments. Emerging strategies, including intravenous brincidofovir and adoptive virus-specific T-cell therapies, represent promising approaches aimed at improving viral clearance while minimizing toxicity. Future research priorities include the establishment of standardized quantitative PCR assays, and validation of clinically meaningful viral load thresholds to guide preemptive therapy. The impact of contemporary transplant approaches, including PTCy and novel cellular therapies, on HAdV epidemiology requires further study. Integration of immune monitoring to identify patients at highest risk for progression may enable personalized therapeutic strategies. Importantly, HAdV epidemiology in allogeneic HCT recipients may differ across geographic regions. Therefore, continued virologic surveillance is needed to better understand circulating genotypes and inform prevention and management strategies. Ultimately, improved understanding of viral kinetics, host immune recovery, and optimized immunotherapeutic interventions will be essential to reducing HAdV-associated morbidity and mortality in this vulnerable population. ACKNOWLEDGEMENTS We thank Dr. Yae-Jean Kim for critically reviewing the manuscript and providing valuable insights that improved the quality of this review. Footnotes Funding: SS and YJL received partial funding from the National Institute of Health/National Cancer Institute Cancer support Grant P30 CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Conflict of Interest: YJL has served as an investigator for AiCuris and has received a research grant paid to her institution by Merck Sharp & Dohme (MSD) and Eurofins Viracor. Data sharing statement: The data that support the findings of this study are available from the corresponding author, upon reasonable request. Author Contributions: Conceptualization: YJL.Data curation: SS, HMJ, YJL.Investigation: SS, HMJ, YJL.Methodology: SS, HMJ, YJL.Project administration: SS, HMJ, YJL.Supervision: YJL.Validation: YJL.Visualization: SS, HMJ, YJL.Writing - original draft: SS, HMJ, YJL.Writing - review & editing: SS, HMJ, YJL. Conceptualization: YJL. Conceptualization: YJL. Data curation: SS, HMJ, YJL. Data curation: SS, HMJ, YJL. Investigation: SS, HMJ, YJL. Investigation: SS, HMJ, YJL. Methodology: SS, HMJ, YJL. Methodology: SS, HMJ, YJL. Project administration: SS, HMJ, YJL. Project administration: SS, HMJ, YJL. Supervision: YJL. Supervision: YJL. Validation: YJL. Validation: YJL. Visualization: SS, HMJ, YJL. Visualization: SS, HMJ, YJL. Writing - original draft: SS, HMJ, YJL. Writing - original draft: SS, HMJ, YJL. Writing - review & editing: SS, HMJ, YJL. Writing - review & editing: SS, HMJ, YJL. References